Ostarine

Ostarine: Mechanism & Pharmacology

Ostarine is a non-steroidal selective androgen receptor modulator (SARM) developed originally by GTx, Inc. under the research designation MK-2866, designed to activate androgen signalling in skeletal muscle and cortical bone while minimising activity in the prostate and sebaceous glands. Its molecular formula is C₁₉H₁₄F₃N₃O₃, and it carries a molecular weight of approximately 389.33 g/mol.

At the molecular level, Ostarine binds the androgen receptor with high affinity, adopting a conformation that recruits co-activator proteins — particularly SRC-1 and TIF2 — in a tissue-selective pattern distinct from that seen with classical anabolic steroids such as testosterone or nandrolone. Because the receptor-ligand complex adopts a slightly different three-dimensional fold compared with steroidal androgens, the transcriptional output differs by tissue: bone and muscle cells receive a strong anabolic signal, whereas androgenic tissues respond with far less stimulation. This selectivity ratio is what makes the compound attractive to researchers and, subsequently, to performance-oriented users.

Pharmacokinetic data gathered in clinical Phase II trials indicate that Ostarine achieves oral bioavailability in the range of 90–95%, which is exceptionally high for a compound taken by mouth without the hepatotoxic 17-alpha alkylation common in oral anabolic steroids. Peak plasma concentration (Cmax) is typically reached within one to three hours of ingestion, and the elimination half-life sits between 23 and 26 hours in healthy adult subjects, supporting once-daily dosing with stable plasma levels. Metabolism proceeds primarily through glucuronidation and hydroxylation rather than through CYP3A4-driven pathways, meaning the interaction profile with common co-administered compounds is relatively contained, though never zero. Renal excretion of metabolites accounts for the majority of elimination.

At the intracellular level, bound androgen receptor translocates to the nucleus, dimerises, and occupies androgen response elements (AREs) on DNA, upregulating genes associated with satellite cell proliferation, nitrogen retention, and IGF-1 expression. Ostarine does not convert to oestradiol via aromatase, nor does it have meaningful affinity for progesterone or glucocorticoid receptors, which distinguishes its side-effect profile sharply from many wet anabolic compounds.

Application Context & User Groups

Research interest in Ostarine has historically centred on three clinical populations: patients with cachexia secondary to cancer, elderly individuals experiencing sarcopenic muscle loss, and post-menopausal women with osteoporosis risk. In a 12-week Phase II trial (GTx, 2011), postmenopausal women and older male subjects receiving 3 mg daily demonstrated statistically significant lean mass gains and improvements in stair-climb power — effects achieved without meaningful changes in prostate-specific antigen or haematocrit.

In the bodybuilding and physique sports context, Ostarine occupies a distinct niche. Users typically turn to it during three scenarios: body recomposition phases where simultaneous fat loss and muscle retention are the goal; injury rehabilitation periods — particularly those involving tendons or ligaments, where androgen receptor expression in connective tissue may support recovery; and as a comparatively mild entry point into SARM-based protocols for individuals who are cautious about more potent agents such as LGD-4033 or RAD-140.

Competitive athletes should note that Ostarine is explicitly included on the World Anti-Doping Agency (WADA) Prohibited List under Section S1.2 (Other Anabolic Agents) and has been since 2008. Detection windows in urine using modern LC-MS/MS methods extend beyond two weeks at typical research doses, and several high-profile doping violations across combat sports and track and field have involved MK-2866, often attributed to contaminated supplements — underscoring the importance of source verification.

Female physique athletes represent a growing user demographic precisely because Ostarine's low androgenic activity means virilisation risk is substantially reduced compared to anabolic steroids, even at doses above the clinical research range. Reported protocols among this group tend to use the lower end of the concentration spectrum over shorter cycles, typically not exceeding eight weeks.

Natural bodybuilders in off-season maintenance phases have also documented its use for preserving lean tissue during moderate caloric deficits, particularly when injury limits training volume. The compound's tolerability profile — characterised primarily by mild suppression of the hypothalamic-pituitary-gonadal (HPG) axis at higher doses and longer durations — makes it arguably the most studied and referenced SARM available.

Range & Selection by Concentration and Pack Size

Our Ostarine category currently features two products across two concentration tiers, giving buyers the flexibility to calibrate intake precisely or to progress from a conservative starting point to a more established protocol.

Ostarine (MK-2866) 10mg/tab 60 Tablets by Elbrus Pharmaceuticals represents the entry-level concentration and is the better-suited option for first-time users, those experimenting with lower-dose recomposition protocols, or female athletes who prefer granular dose control. At 10 mg per tablet, each pack of 60 tablets provides a full eight-week supply at the commonly referenced 10 mg daily dose — sufficient to assess individual response, observe lean mass retention effects, and evaluate any axis suppression before committing to a higher intake. Elbrus Pharmaceuticals has established a reputation for consistent tablet weight uniformity and clearly labelled active content, both important factors when working with compounds where precise dosing materially affects the outcome. The 60-tablet pack size also makes it economical for a complete single cycle without surplus stock.

Ostarine 15mg/tab 50 Tablets by Rich Piana 5% Nutrition sits at the higher concentration tier and caters to intermediate users who have already established baseline tolerability and are seeking a more pronounced anabolic stimulus. At 15 mg per tablet, this product aligns well with the upper range of doses seen in clinical efficacy trials and is practical for users running six- to seven-week cycles. Rich Piana 5% Nutrition brings a brand identity rooted in high-volume, no-compromise bodybuilding culture, and the product line adheres to this philosophy with a higher per-tablet concentration that reduces daily pill burden. The 50-tablet pack provides approximately seven weeks at 15 mg daily, making it well matched to users who prefer moderate-length cycles followed by structured recovery periods.

Choosing between tiers is straightforward when framed by experience and objective. New users or those prioritising connective tissue support and lean retention should start with the 10 mg option from Elbrus Pharmaceuticals and reassess after one complete cycle. Users targeting more visible lean mass accrual or running recomposition phases with a meaningful training history should consider the 15 mg option from Rich Piana 5% Nutrition. Neither product requires split dosing given the compound's 23–26-hour half-life, and both formats are tablet-based, eliminating the measurement variability associated with liquid research formulations.

Frequently Asked Questions

What is the difference between 10 mg and 15 mg Ostarine tablets in practice?

The 10 mg dose aligns with clinical research ranges and suits first-time users or female athletes seeking lean retention with minimal HPG axis suppression. The 15 mg dose is associated with more pronounced anabolic output and is better suited to experienced users in recomposition or lean-bulk phases. The practical difference is response magnitude and degree of transient hormonal suppression post-cycle.

Does Ostarine require a post-cycle therapy (PCT) protocol?

Ostarine causes dose- and duration-dependent suppression of endogenous testosterone production. At 10 mg for eight weeks or fewer, suppression is generally mild and many users recover naturally. At 15 mg or beyond eight weeks, a structured PCT using a SERM such as nolvadex or clomid is commonly recommended to restore HPG axis function more efficiently. Individual response varies and monitoring bloodwork is advisable.

How long does Ostarine remain detectable in urine?

Using current LC-MS/MS analytical methods, Ostarine metabolites are detectable in urine for approximately two to three weeks following the last dose at typical research quantities. However, detection windows can extend further depending on individual metabolism, dose duration, and the sensitivity thresholds of the specific test employed. Any athlete subject to anti-doping controls should treat Ostarine as a prohibited substance with a significant detection risk.